(Press-News.org) Early results show that a new combination drug therapy is safe and effective against advanced skin cancer in patients who were not able to have their tumors surgically removed.
The drug combination is among the first, researchers say, to demonstrate the potential value of a live common cold virus, a coxsackievirus, to infect and kill cancer cells.
The Phase I study, led by a researcher at NYU Langone Health and its Perlmutter Cancer Center, is also among the first to show how such oncolytic viruses can safely boost the action of widely used cancer therapies that help the body's immune defense system detect and kill cancer cells. Currently, such immunotherapies are only effective in shrinking melanoma tumors in just over a third of patients who receive them.
The new study results showed that injections of experimental coxsackievirus drug V937, along with pembrolizumab, an immunotherapy drug known as pembro or Keytruda, was well tolerated. Moreover, the combined treatment shrank melanoma tumors in nearly half (47 percent) of 36 men and women who received the therapy every few weeks for at least two years.
Researchers say most side effects, such as rash and fatigue, were minimal, while 13 patients (36 percent) had serious immune reactions in the liver, stomach, or lungs, not unlike side effects that are known to happen with pembrolizumab alone.
Set for presentation at the annual meeting of the American Association for Cancer Research online April 10, the study also showed that eight patients who received both drugs (22 percent) experienced complete remission, with no remaining signs of skin cancer.
"Our initial study results are very promising and show that this oncolytic virus injection, a modified coxsackievirus, when combined with existing immunotherapy is not only safe but has the potential to work better against melanoma than immunotherapy alone," says study senior investigator and medical oncologist Janice Mehnert, MD.
Mehnert, a professor at NYU Grossman School of Medicine and associate director of clinical research at Perlmutter Cancer Center, cautions that further testing, already underway, would have to prove successful before the combination treatment could become a "standard of care," or go-to therapy, for patients with advanced melanoma, meaning melanoma that has spread to other parts of the body.
She adds that the next phase of clinical trials will involve patients with melanoma that has become widespread, as well as in patients whose tumors, if shrunken by the drug combination, could be more easily removed by surgery.
Among the study's other findings was that patients least likely to respond to immunotherapy alone were those who responded best to the combined treatment. Patients, for example, who responded best had less of the chemical receptors (PDL1) on the surfaces of cancer cells that are blocked by pembrolizumab than patients who did not respond as well.
Researchers say further experiments are needed to determine how V937 changes the molecular makeup of the tissues immediately surrounding tumors.
"Our goal is to determine if the virus turns the tumor microenvironment from 'friendly' to one that is 'unfriendly,' making the cancer cells more vulnerable to pembrolizumab," says Mehnert.
As part of the latest study, volunteers, mostly seniors, enrolled at three cancer clinics, including Rutgers Cancer Institute in New Brunswick, NJ; Gabrail Cancer Center in Canton, Ohio; and John Wayne Cancer Institute in Santa Monica, Calif.
Scientists have known since the 1800s that some cancer patients who suffered from infections, later tied to bacteria or viruses that cause measles and herpes, often experience tumor shrinkage. Recent technological advances in genetic engineering have allowed scientists to retool viruses to target specific molecules on the surface of cancer cells to more easily infect them.
INFORMATION:
Funding support for the study, known as CAPRA, was provided by Viralytics, the manufacturer of the V937 drug used in the experiments, and by Merck of Kenilworth, NJ, which owns Viralytics and produces pembrolizumab, the other drug involved in the research. More information about the trial can be found online at https://clinicaltrials.gov/ct2/show/NCT02565992.
Besides Mehnert, other researchers involved in the study are study investigators Ann Silk at Dana-Farber Cancer Institute in Boston; Steven O'Day at John Wayne Cancer Institute in Santa Monica, Calif.; Howard Kaufman at Massachusetts General Hospital in Boston; Casey Imbergamo, Daniella Portal, Edwin Zambrano-Acosta, Marisa Palmeri, Daniel Medina, and Joshua Vieth at Rutgers University; Seymour Fein at Seattle Cancer Care Alliance; Cai Wu and Leslie Guerreiro at Merck; Andrew Zloza at Rush University in Chicago; Bernard Fox and Carmen Ballesteros-Merino at Providence Portland Medical Center in Ore.; Darren Shafren at ImmVirX in New Lambton Heights, Australia; and Mark Grose at Viralytics in Kenilworth, NJ.
Media Inquiries:
David March
212-404-3528
david.march@nyulangone.org
An international team working at the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) used a unique X-ray instrument to learn new things about lithium-rich battery materials that have been the subject of much study for their potential to extend the range of electric vehicles and the operation of electronic devices.
The researchers focused their investigations on a material called lithium manganese oxide (Li2MnO3), the extreme example of so-called "lithium-rich" materials, containing the largest amount of lithium possible within this family of materials. A recently developed tenet of the ...
A dementia diagnosis turns the world upside down, not only for the person affected but also for their relatives, as brain function gradually declines. Those affected lose their ability to plan, remember things or behave appropriately. At the same time, their motor skills also deteriorate. Ultimately, dementia patients are no longer able to handle daily life alone and need comprehensive care. In Switzerland alone, more than 150,000 people share this fate, and each year a further 30,000 new cases are diagnosed.
To date, all attempts to find a drug to cure this disease ...
As demonstrated by multiple studies over the years, women who breastfeed have a lower risk for developing cardiovascular disease and diabetes when compared to those who don't or can't. However, the mechanisms by which these risks are reduced for lactating women are still not fully understood.
Duke Appiah, Ph.D., an assistant professor of public health at the Texas Tech University Health Sciences Center and director of the university's master's program in public health, said the presence of excess fat, specifically visceral and pericardial fat could help explain this finding. Using that hypothesis, Appiah and a team of researchers recently completed a study titled, "The ...
Dengue risk is exacerbated in highly populated areas of Brazil after extreme drought because of improvised water containers housing mosquitoes, suggests a new study in Lancet Planetary Health.
The research was led by the London School of Hygiene & Tropical Medicine's (LSHTM) Centre on Climate Change & Planetary Health and Centre for the Mathematical Modelling of Infectious Diseases. Using advanced statistical modelling techniques, the team predicted the timing and intensity of dengue risk in Brazil from extreme weather patterns.
The risk of dengue ...
Data collected from 337 cities across 18 countries show that even slight increases in ambient carbon monoxide levels from automobiles and other sources are associated with increased mortality.
A scientific team led by Yale School of Public Health Assistant Professor Kai Chen analyzed data, including a total of 40 million deaths from 1979 to 2016, and ran it through a statistical model. The research, published today in The Lancet Planetary Health, also found that even short-term exposure to ambient carbon monoxide (CO) -- at levels below the current air quality guidelines and considered ...
In a study of over 73 million delivery hospitalizations during a 19-year period in the United States, researchers at Columbia University Mailman School of Public Health and Columbia University Irving Medical Center found that failure to rescue from severe maternal morbidity contributes more than a half of the 3-fold difference in maternal mortality between Black women and White women. Failure to rescue refers to death resulting from severe maternal morbidity such as eclampsia, acute heart failure, and sepsis. The findings are published in the journal Obstetrics and Gynecology.
"Despite ...
When most Americans imagine an archaeologist, they picture someone who looks like Indiana Jones. Or, perhaps, Lara Croft, from the Tomb Raider game. White, usually male but occasionally female, digging up the spoils of a vanished culture in colonized lands.
Depictions of archaeologists in popular culture mirror reality. Many scholars have noted the experts institutions recognize as authorities to discuss or represent the past are overwhelmingly white and mostly male. Archaeology has also been a tool colonizing countries use to consolidate and justify their domination. As a new open-access paper in American Antiquity points out, the first doctoral degree in archaeology was not granted to a Black woman until 1980.
First author Ayana Omilade Flewellen, ...
Cambridge, Mass. - When the first COVID-19 vaccines were approved for emergency use in December 2020, healthcare systems across the Unites States needed to rapidly design and implement their own approaches to distribute COVID-19 vaccines equitably and efficiently. This new role has required Beth Israel Lahey Health (BILH) to develop new strategies and build large operational teams to organize and successfully vaccinate more than 14,000 patients a week across Eastern Massachusetts. In an Insight article published in JAMA Health Forum, Leonor Fernandez, MD, Assistant Professor of Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center (BIDMC) and Peter Shorett, MPP, Chief Integration Officer at ...
April 8, 2021 - Women undergoing surgery to treat stress urinary incontinence (SUI) are not at increased risk of developing pelvic cancers, according to a large-scale, population-based study in The Journal of Urology®, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
"In a very large population with extended follow-up, we found no increase in the risk of any pelvic malignancy in women who underwent stress urinary incontinence surgery," comments lead author Humberto ...
Detecting and analyzing breast cancer goes beyond the initial discovery of the cancer itself. If a patient has a tumor removed and it needs to be analyzed to determine further treatment, it might be OK for the results to take 24 hours. But if the patient is still on the operating table and clinicians are waiting to make sure no cancer cells are present along the edges of the removed tumor, results need to be nearly immediate.
A paper titled, "Breast cancer histopathology using infrared spectroscopic imaging: The impact of instrumental configurations," ...
